Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STING Trial: UD TGFβi NK Cells + Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma
NCT06450041Phase 2Recruiting
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of transforming growth factor-beta-imprinted natural killer cells in neuroblastoma, sponsored by New Advances in Neuroblastoma Therapy. Started Dec 2024; status: recruiting.
02
Drugs
transforming growth factor-beta-imprinted natural killer cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06450041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450041.